Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (129)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (13)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    D'Angelo, S. P.; Rosenbaum, E.; Gularte MeĢrida, R.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
    Meeting Abstract

    Betof Warner, A.; Postow, M. A.; Panageas, K.; Smithy, J. W.; Schoenfeld, A. J.; Wolchok, J. D.; Shoushtari, A. N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
    Meeting Abstract

    Hays, J. L.; Friedman, C. F.; Lakhani, N.; Anderson, C. K.; Buscema, J.; Duska, L. R.; Hamilton, E. P.; Taylor, S. E.; Carrington, C.; Burger, R. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors
    Meeting Abstract

    McKean, M.; Spira, A. I.; Rosen, E.; Subbiah, V.; Moreno, V.; Gambardella, V.; Vieito, M.; Saavedra, O.; Cousin, S.; Cassier, P. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets)
    Meeting Abstract

    Sui, J. S. Y.; Wilcox, J.; Tischfield, S.; Choudhury, N. J.; Riely, G. J.; Kris, M. G.; Boire, A. A.; Yu, H. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of benefit to radiation for oligoprogressive disease in EGFR -mutant metastatic non-small cell lung cancer patients treated with osimertinib
    Meeting Abstract

    Chen, M. F.; Ma, J.; Kris, M. G.; Gomez, D. R.; Yu, H. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Rosenbaum, E.; Cordover, E.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; Chan, J. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings
    Meeting Abstract

    Walsh, M. F.; Fiala, E.; Birsoy, O.; Haque, T.; Stein, E. M.; Shukla, N.; Sulis, M. L.; Goldberg, A. D.; Rana, S.; Khurram, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition
    Meeting Abstract

    Walsh, M. F.; Mukherjee, S.; Gao, M.; Fiala, E.; Mauguen, A.; Kemel, Y.; Bandlamudi, C.; Mehine, M.; Carlo, M. I.; Murciano-Goroff, Y. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save